Fifteen Scientific Studies with 22nd Century''s Reduced Nicotine SPECTRUM?

Source from:  Business Wire 03/11/2016

22nd Century Group, Inc. a plant biotechnology company that is a leader in tobacco harm reduction, announced today that the initial results of an unprecedented number - more than fifteen - independent scientific studies involving the Company's SPECTRUM? reduced nicotine tobacco cigarettes were presented by independent scientific researchers at the 22nd Annual Meeting of the Society for Research on Nicotine & Tobacco ("SRNT") held on March 2 - 5, 2016, in Chicago, Illinois. The annual event was highly attended by participants from around the world, including acclaimed university scientists, FDA and other regulators, and industry professionals. The initial results of the independent scientific studies involving the Company's proprietary reduced nicotine tobacco cigarettes adds to the mounting body of evidence which shows that the Company's Very Low Nicotine cigarettes reduce cigarette consumption and assist in smoking cessation.

Due to the fact that the results presented at the SRNT Conference are preliminary and not yet published, 22nd Century is not yet able to release or cite specific study data; however, this link from the SRNT.org website is to the summaries of the initial results of all the scientific studies that were presented at the SRNT Annual Meeting, including the studies on the Company's reduced nicotine tobacco (see abstract numbers: SYM1B, PA17-1, PA22-5, POS1-19, POS1-50, POS1-74, POS1-104, POS1-107, POS1-129, POS1-137, POS1-146, POS1-148, PA8-5, POS2-6, POS4-20, POS4-95).

"There is a mounting body of evidence that demonstrates that 22nd Century's proprietary Very Low Nicotine cigarettes are a highly useful tool in helping smokers to quit smoking with no withdrawal symptoms and no exposure to new toxicants," explained Dr. Paul Rushton, 22nd Century's Vice President of Plant Biotechnology. "As a result of the numerous independent trials that have already been conducted, we believe a national nicotine reduction policy would have broad beneficial effects on health in the U.S."

Henry Sicignano, III, President and Chief Executive Officer of 22nd Century Group, stated "We are very proud of our mission - to reduce the harm caused by smoking - and we are honored to have so many prestigious independent researchers conducting important studies with our proprietary Very Low Nicotine tobacco. We look forward to working with interested researchers around the world to design and provide the exact types of Very Low Nicotine research cigarettes that they desire to fit their independent research plans. Ultimately, we hope to be able to provide our highly effective and exciting products to consumers in the U.S. as soon as permitted by the appropriate regulators." Enditem